ALNY News and Press, Alnylam Pharmaceuticals Inc. From 10/18/21

Alnylam Receives Positive Reimbursement Recommendation from the Canadian Agencies for Drugs and Technology in Health (CADTH) for use of GIVLAARI® for the Treatment of Acute Hepatic Porphyria (AHP) in Adults Canada NewsWire -- GIVLAARI reduces Chronic Pain, Improve...

A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. Focus on IBB. A list of cheap stocks. For further details see: IBB: Healthcare Dashboard For October

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the third quarter ending September 30, 2021 on Thursday, October 28, 2021, before the U.S. financial markets open. Management will provi...

Buying low and selling high is a winning investment strategy, but it's a lot easier said than done. That's because the best stocks tend to keep on rising while bargain-conscious shoppers wait for an entry point. Palo Alto Networks (NYSE: PANW) , Alnylam Pharmaceuticals (NA...

− Alnylam will provide a $1 Million Grant to Acumen America and will serve as an Anchor Partner of their Health Equity Portfolio – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced the launch of Alnylam Cha...

Alnylam is seeing sales ramp and could get more drugs approved in January and April 2022. Heavy R&D investment means a long path to profitability. I am neutral overall, based on valuation. For further details see: Alnylam: Potential Is In Line With Current Valuation ...

− Reveals Hexadecyl (C16) Lipophilic Conjugate for Potent and Effective Delivery of siRNAs in the CNS – − Presents Pre-clinical Data with IKARIA Platform Demonstrating Potential to Achieve Over 90% Target Knockdown with an Annual Dosing Regimen – ...

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Chardan Virtual 5 th Annual Genetic Medicines Conference on Tuesday, October 5, 2021 at 2:30 pm ET. A live audio webcas...

ONPATTRO® (patisiran) Now Reimbursed in Canada For the Treatment of Hereditary Transthyretin (TTR)-Mediated Amyloidosis (hATTR) Canada NewsWire ONPATTRO is the only treatment that has demonstrated improvement in both polyneuropathy and quality of life measure...

Read the full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)